Teva Pharmaceuticals Exceeds Revenue Expectations, Driven by Specialty Drugs
Translated & summarized from Calcalist by baba
Teva Pharmaceuticals reported third-quarter revenues of $4.4 billion, exceeding forecasts and boosting its market value to nearly $50 billion. While overall revenue fell 2% year-over-year due to weaker generic drug sales, specialty drugs like Austedo, Ajovy, and Uzedy saw a 33% revenue increase. The company's adjusted net income was approximately $1 billion, surpassing expectations.
The story in 5 lines · by baba
- Teva Pharmaceuticals reported Q3 revenues of $4.4 billion, exceeding analyst expectations.
- Specialty drugs Austedo, Ajovy, and Uzedy generated $1.1 billion in revenue, a 33% increase.
- Overall Q3 revenue decreased by 2% compared to the same period last year.
- Adjusted net income was approximately $1 billion, or 86 cents per share.
- The company's market valuation reached nearly $50 billion recently.
Teva Pharmaceuticals reported third-quarter revenues of $4.4 billion, surpassing analyst expectations of $4.2 billion and contributing to a recent market valuation of nearly $50 billion. Despite this positive performance, overall revenues saw a 2% decrease compared to the same quarter last year, primarily due to a decline in generic drug sales.
This weakness in the generics sector was partially offset by strong results from Teva's specialty drugs, including Austedo, Ajovy, and Uzedy. These three medications generated $1.1 billion in revenue, marking a significant 33% increase year-over-year. This growth in higher-margin products boosted the gross profit margin to 55.5%, up from 51.4% in the prior-year period.
The company posted adjusted net income of approximately $1 billion, or 86 cents per share, exceeding the forecasted 73 cents per share. However, net income under accounting rules was $233 million, or 20 cents per share. This lower figure was impacted by write-downs and provisions for legal settlements, which also led to a decrease in operating profit to $714 million from $882 million in the corresponding quarter, despite the improved gross profitability.
Mentioned
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
